Chapter 36
Liver Metastases from Endocrine Tumors
Clayton D. Knox MD, MBA,
C. Wright Pinson MD, MBA,
Clayton D. Knox MD, MBA
Vanderbilt University School of Medicine, Nashville, TN, USA
Search for more papers by this authorC. Wright Pinson MD, MBA
Professor of Surgery
Deputy Vice-Chancellor for Health Affairs, Vanderbilt University Medical Center, Nashville, TN, USA
Search for more papers by this authorClayton D. Knox MD, MBA,
C. Wright Pinson MD, MBA,
Clayton D. Knox MD, MBA
Vanderbilt University School of Medicine, Nashville, TN, USA
Search for more papers by this authorC. Wright Pinson MD, MBA
Professor of Surgery
Deputy Vice-Chancellor for Health Affairs, Vanderbilt University Medical Center, Nashville, TN, USA
Search for more papers by this authorBook Editor(s):Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Stefan Breitenstein MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorFirst published: 09 December 2009
Summary
This chapter contains sections titled:
-
Introduction
-
Primary tumors
-
Imaging for diagnosis, staging
-
and follow-up
-
Treatment
-
Conclusion
-
References
-
Self-assessment questions
-
Self-assessment answers
References
- Chen H, Haracre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187: 88–93.
- Moertel CG. An odyssee in the land of small tumors. J Clin Oncol 1987; 5: 1503–22.
- Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–59.
- Kloppel G, Heitz PU, Capella C, et al. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 1996; 20: 132–41.
- Naunheim KS, Zeitels J, Kaplan EL, et al. Rectal carcinoid tumors ndash; treatment and prognosis. Surgery 1983; 94: 670–5.
- Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 23–32.
- Thompson GB, Heerden JA, Martin JK, et al. Carcinoid tumors of the gastrointestinal tract: presentation, management, and prognosis. Surgery 1985; 98: 1054–63.
- Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994; 31: 77–82.
- Steinmueller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47–62.
- Bilimoria KY, Tomlinson JS, Merkow RP, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg 2007; 11: 1460–7.
- Vinik AI, Strodel WE, Eckhauser FE, et al. Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 1987; 14: 263–81.
- Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1987; 317: 1200–09.
- Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 1995; 25: 272–8.
- Martin, WH, Delbeke D. Oncologic imaging. In: Habibian MR, Delbeke D., Martin WH, Sandler MP, eds. Nuclear Medicine Imaging: A Teaching File. Baltimore: Williams & Wilkins, 1999: 619–722.
- Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508–18.
- Imam H, Eriksson B, Lukinius A, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997; 36: 607–14.
- Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Int Med Res 1995; 237: 269–75.
- Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430–8.
- Chung MH, Pisegna S, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001; 130: 954–62.
- Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130: 677–85.
- Andersson T, Wilander E, Eriksson B, et al. Effects of interferon on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 1990; 50: 3413–15.
- Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996; 7: 453–463.
- McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091–6.
- Foster J, Lundy J. Pathology of liver metastases. Curr Probl Surg 1981; 18: 157–63.
- Clary B. Treatment of isolated neuroendocrine liver metastases. J Gastrointest Surg 2006; 10: 332–4.
- Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13: 572–81.
- Knox CD, Feurer ID, Wise PE, et al. Survival and functional quality of life after resection for hepatic carcinoid metastasis. J Gastrointest Surg 2004; 8: 653–9.
- Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776–83.
- Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 2006; 141: 1000–4.
- Grazi GL, Cescon M, Pierangeli F, et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 2000; 47: 481–6.
- Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29–37.
- Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 2000; 190: 432–45.
- Coppa J, Pulvirenti A, Schiavo M, et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplant Proc 2001; 33: 1537–9.
- Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 2001; 25: 689–92.
-
Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995; 76: 501–9.
10.1002/1097-0142(19950801)76:3<501::AID-CNCR2820760322>3.0.CO;2-X CAS PubMed Web of Science® Google Scholar
-
Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 1998; 14: 175–83.
10.1002/(SICI)1098-2388(199803)14:2<175::AID-SSU10>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142: 10–19.
- Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235–40.
- Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998; 66: 1307–12.
- LeTreut YP, Gregoire E, Belghiti J, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: An 85-case French multicentric report. Am J Transplant 2008; 8: 1205–13.
- Marín C, Robles R, Fernández JA, et al. Role of liver transplantation in the management of unresectable neuroendocrine liver metastases. Transplant Proc 2007; 39: 2302–3.
- Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007; 13: 327–33.
- Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004; 8: 208–12.
- Frilling A, Rogiers X, Malago M, et al. Treatment of liver metastases in patients with neuroendocrine tumors. Langenbeck's Arch Surg 1998; 383: 62–70.
- Ringe B, Lorf T, Dopkens K, Canelo R. Treatment of hepatic metastases from gastroenteropancreatic neuroendocrine tumors: role of liver transplantation. World J Surg 2001; 25: 697–99.
- Moertel CG, Lefkopoulo M, Lipistz S, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519.
-
Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227–32.
10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- Anthony LB, Woltering EA, Espanan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Seminars Nucl Med 2002; 32: 123–32.
- Waldherr C, Schumacher T, Maecke HR, et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med Mol Imaging 2002; 29 (Suppl 1): S100.
- Paganelli G, Bodei L, Junak D, et al. 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002; 66: 393–8.
- Bushnell D. Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors. J Gastrointest Surg 2006; 10: 335–6.
- Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754–62.
- Aune S, Schistad G. Carcinoid liver metastases treated with hepatic dearterialization. Am J Surg 1972; 123: 715–17.
- Carrasco CH, Charnsangavej C, Ajani J, et al. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986; 147: 149–154.
- Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188: 1201–7.
- Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104: 1590–602.
- Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116: 1111–17.
- Kamat PP, Gupta S, Ensor JE, et al. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol 2008; 31: 299–307.
- Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007; 18: 847–55.
- Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for meteastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36–43.
